Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study

PurposeThe need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after n...

Descripció completa

Dades bibliogràfiques

Autors principals:	Shu-Han Xie, Li-Tao Yang, Hai Zhang, Zi-Lu Tang, Zhi-Wei Lin, Yi Chen, Zhi-Nuan Hong, Rong-Yu Xu, Wan-Li Lin, Ming-Qiang Kang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-02-01
Col·lecció:	Frontiers in Immunology
Matèries:	adjuvant therapy neoadjuvant chemoimmunotherapy esophageal cancer propensity score matching recurrence-free survival
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1332492/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!